Comprehensive Investigation of a Tyrosine Kinase Inhibitor-Resistant Gene Zeste White 10 in Hepatocellular Carcinoma
Abstract Background: Tyrosine kinase inhibitors (TKIs) are first-line therapies for hepatocellular carcinoma (HCC), but the drug resistance restricts the long-term clinical outcomes. This study aimed to investigate the expression patterns and possible clinical significance of a TKI-resistant gene zeste white 10 (ZW10) in HCC. Methods: Clustered regularly interspaced short palindromic repeats (CRISPR) screening was conducted to obtain TKI-resistant genes. Pan-cancer analysis was employed to analyze the expression landscape of the critical TKI-resistant gene ZW10. Transcriptional expression data for ZW10 were
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
